The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo
Abstract
Two substrates of insulin-degrading enzyme (IDE), amyloid β-protein (Aβ) and insulin, are critically important in the pathogenesis of Alzheimer's disease (AD) and type 2 diabetes mellitus (DM2), respectively. We previously identified IDE as a principal regulator of Aβ levels in neuronal and microglial cells. A small chromosomal region containing a mutant IDE allele has been associated with hyperinsulinemia and glucose intolerance in a rat model of DM2. Human genetic studies have implicated the IDE region of chromosome 10 in both AD and DM2. To establish whether IDE hypofunction decreases Aβ and insulin degradation in vivo and chronically increases their levels, we characterized mice with homozygous deletions of the IDE gene (IDE −/−). IDE deficiency resulted in a >50% decrease in Aβ degradation in both brain membrane fractions and primary neuronal cultures and a similar deficit in insulin degradation in liver. The IDE −/− mice showed increased cerebral accumulation of endogenous Aβ, a hallmark of AD, and had hyperinsulinemia and glucose intolerance, hallmarks of DM2. Moreover, the mice had elevated levels of the intracellular signaling domain of the β-amyloid precursor protein, which was recently found to be degraded by IDE in vitro . Together with emerging genetic evidence, our in vivo findings suggest that IDE hypofunction may underlie or contribute to some forms of AD and DM2 and provide a mechanism for the recently recognized association among hyperinsulinemia, diabetes, and AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A is cleared from the brain via several clearance mechanisms, such as uptake and degradation by astro- cytes and microglia, 7,8 via A-degrading enzymes, such as neprilysin, endothelin-converting enzyme, and insulindegrading enzyme, 40 -42 and via transport by cerebral cells across the blood-brain barrier into the blood.”
From Lipoprotein Receptor-Related Protein-1 Mediates Amyloid-β-Mediated Cell Death of Cerebrovascular Cells (2007) · cites this paper as [41]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
A Transcriptively Active Complex of APP with Fe65 and Histone Acetyltransferase Tip60
Cao, X., & Südhof, T. C. (2001) · Science · doi:10.1126/science.1058783 · Cited by 1,202
Ferrannini, E., Natali, A., Bell, P., Cavallo-Perin, P., Lalic, N., & Mingrone, G. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119628 · Cited by 898
Insulin-degrading Enzyme Regulates Extracellular Levels of Amyloid β-Protein by Degradation
Qiu, W. Q., Walsh, D. M., Ye, Z., Vekrellis, K., Zhang, J., Podlisny, M. B., Rosner, M. R., Safavi, A., Hersh, L. B., & Selkoe, D. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.49.32730 · Cited by 812
Self-citationAdvanced glycation end products contribute to amyloidosis in Alzheimer disease
Vitek, M. P., Bhattacharya, K., Glendening, J. M., Stopa, E., Vlassara, H., Bucala, R., Manogue, K., & Cerami, A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.11.4766 · Cited by 806
Risk of Dementia among Persons with Diabetes Mellitus: A Population-based Cohort Study
Leibson, C. L., Rocca, W. A., Hanson, V. A., Cha, R., Kokmen, E., O'Brien, P. C., & Palumbo, P. J. (1997) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009106 · Cited by 700
Memory improvement following induced hyperinsulinemia in Alzheimer’s disease
Craft, S., Newcomer, J., Kanne, S., Dagogo-Jack, S., Cryer, P., Sheline, Y., Luby, J., Dagogo-Jack, A., & Alderson, A. (1996) · Neurobiology of Aging · doi:10.1016/0197-4580(95)02002-0 · Cited by 538
Age at Onset in Two Common Neurodegenerative Diseases Is Genetically Controlled
Li, Y.-J., Scott, W. K., Hedges, D. J., Zhang, F., Gaskell, P. C., Nance, M. A., Watts, R. L., Hubble, J. P., Koller, W. C., Pahwa, R., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/339815 · Cited by 312
Turnover of Amyloid β-Protein in Mouse Brain and Acute Reduction of Its Level by Phorbol Ester
Savage, M. J., Trusko, S. P., Howland, D. S., Pinsker, L. R., Mistretta, S., Reaume, A. G., Greenberg, B. D., Siman, R., & Scott, R. W. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-05-01743.1998 · Cited by 213
Insulin-degrading enzyme identified as a candidate diabetes susceptibility gene in GK rats
Fakhrai-Rad, H. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.14.2149 · Cited by 155
Research works printed but not linked: 48
- 10.1210/edrv.19.5.0349 · DOI · Paper page
- 10.2337/diab.33.1.64 · DOI
- 10.1523/JNEUROSCI.20-05-01657.2000 · DOI · Paper page
- 10.1074/jbc.M006170200 · DOI · Paper page
- 10.1016/S0968-0004(01)01876-X · DOI · Paper page
- F Authier, B I Posner, J J M Bergeron Clin Invest Med 19, 149–160 (1996).
- 10.1086/321185 · DOI
- 10.1086/323249 · DOI · Paper page
- 10.2337/diabetes.51.3.833 · DOI · Paper page
- 10.1074/jbc.272.10.6641 · DOI · Paper page
- 10.1021/bi011193l · DOI
- 10.1523/JNEUROSCI.20-23-08745.2000 · DOI
- 10.1046/j.1471-4159.2001.00012.x · DOI · Paper page
- 10.1126/science.1059946 · DOI · Paper page
- 10.1074/jbc.C200642200 · DOI · Paper page
- 10.1126/science.290.5500.2302 · DOI · Paper page
- 10.1016/S0304-3940(02)00243-4 · DOI
- 10.1007/s00439-001-0614-1 · DOI
- 10.1016/S0304-3940(02)00586-4 · DOI
- 10.1126/science.290.5500.2304 · DOI · Paper page
- 10.1126/science.290.5500.2303 · DOI · Paper page
- 10.1074/jbc.M111571200 · DOI · Paper page
- 10.1074/jbc.C100447200 · DOI · Paper page
- 10.1046/j.1471-4159.2001.00516.x · DOI · Paper page
- 10.1016/S0092-8674(02)00809-7 · DOI · Paper page
- 10.1038/33423 · DOI · Paper page
- 10.1083/jcb.93.1.97 · DOI · Paper page
- M B Podlisny, D Tolan, D J Selkoe Am J Pathol 138, 1423–1435 (1991).
- 10.1006/nbdi.1997.0129 · DOI · Paper page
- 10.1038/383710a0 · DOI · Paper page
- 10.1016/S0531-5565(00)00157-1 · DOI
- 10.1073/pnas.97.16.9299 · DOI
- 10.1084/jem.181.6.2271 · DOI · Paper page
- 10.1016/0092-8674(95)90073-X · DOI · Paper page
- 10.1523/JNEUROSCI.20-11-04050.2000 · DOI · Paper page
- 10.2337/diab.23.6.536 · DOI
- 10.1016/S0002-9440(10)65184-X · DOI · Paper page
- 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M · doi:10.1002/1531-8249(199912)46:6<860::aid-ana8>3.0.co;2-m
- 10.2337/diabetes.49.12.2094 · DOI · Paper page
- 10.1053/meta.2001.20170 · DOI
- 10.1016/S0021-9258(18)77189-5 · DOI
- 10.1007/s001250100580 · DOI · Paper page
- 10.1212/WNL.53.9.1937 · DOI · Paper page
- 10.1212/WNL.52.5.971 · DOI · Paper page
- 10.2337/diacare.20.5.792 · DOI · Paper page
- 10.1093/ageing/23.5.396 · DOI
- 10.1016/0006-3223(91)90158-I · DOI
- 10.1016/S0002-9440(10)65659-3 · DOI · Paper page
Cited by
Items 101–189 of 189
Luchsinger, J. A., Perez, T., Chang, H., Mehta, P., Steffener, J., Pradabhan, G., Ichise, M., Manly, J., Devanand, D. P., & Bagiella, E. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150493 · Cited by 285
“Metformin is not directly active in the brain [38], and we postulate that it acts on the AD process through reduction of peripheral insulin levels that affect brain clearance of A [76–78].”
Biological metals and Alzheimer's disease: Implications for therapeutics and diagnostics
Duce, J. A., & Bush, A. I. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.04.003 · Cited by 283
Diabetes is related to cerebral infarction but not to AD pathology in older persons
Arvanitakis, Z., Schneider, J. A., Wilson, R. S., Li, Y., Arnold, S. E., Wang, Z., & Bennett, D. A. (2006) · Neurology · doi:10.1212/01.wnl.0000247053.45483.4e · Cited by 281
Brain Insulin Resistance and Hippocampal Plasticity: Mechanisms and Biomarkers of Cognitive Decline
Spinelli, M., Fusco, S., & Grassi, C. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00788 · Cited by 280
Insulin signaling pathway and related molecules: Role in neurodegeneration and Alzheimer's disease
Akhtar, A., & Sah, S. P. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104707 · Cited by 279
PPARγ Agonists as Therapeutics for the Treatment of Alzheimer's Disease
Landreth, G., Jiang, Q., Mandrekar, S., & Heneka, M. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.003 · Cited by 277
Götz, J., Streffer, J. R., David, D., Schild, A., Hoerndli, F., Pennanen, L., Kurosinski, P., & Chen, F. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001508 · Cited by 274
The role of type 2 diabetes in neurodegeneration
Verdile, G., Fuller, S. J., & Martins, R. N. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.04.008 · Cited by 272
Insulin Resistance and Alzheimer’s Disease: Bioenergetic Linkages
Neth, B. J., & Craft, S. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00345 · Cited by 272
Alzheimer's disease and type 2 diabetes: a critical assessment of the shared pathological traits
Chatterjee, S., & Mudher, A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00383 · Cited by 270
Farris, W., Mansourian, S., Leissring, M. A., Eckman, E. A., Bertram, L., Eckman, C. B., Tanzi, R. E., & Selkoe, D. J. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63229-4 · Cited by 269
Self-citationBiessels, G. J., & Kappelle, L. J. (2005) · Biochemical Society Transactions · doi:10.1042/bst0331041 · Cited by 266
Aβ-degrading enzymes: potential for treatment of Alzheimer disease
Miners, J. S., Barua, N., Kehoe, P. G., Gill, S., & Love, S. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3182345e46 · Cited by 265
Carro, E., & Torres-Aleman, I. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.02.050 · Cited by 262
Insulin resistance predicts brain amyloid deposition in late middle‐aged adults
Willette, A. A., Johnson, S. C., Birdsill, A. C., Sager, M. A., Christian, B., Baker, L. D., Craft, S., Oh, J., Statz, E., Hermann, B. P., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.03.011 · Cited by 262
Grarup, N., Rose, C. S., Andersson, E. A., Andersen, G., Nielsen, A. L., Albrechtsen, A., Clausen, J. O., Rasmussen, S. S., Jørgensen, T., Sandbæk, A., et al. (2007) · Diabetes · doi:10.2337/db07-0856 · Cited by 260
Atypical aging in down syndrome
Zigman, W. B. (2013) · Developmental Disabilities Research Reviews · doi:10.1002/ddrr.1128 · Cited by 260
Iwata, N., Mizukami, H., Shirotani, K., Takaki, Y., Muramatsu, S.-I., Lu, B., Gerard, N. P., Gerard, C., Ozawa, K., & Saido, T. C. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4792-03.2004 · Cited by 257
Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones
Maianti, J. P., McFedries, A., Foda, Z. H., Kleiner, R. E., Du, X. Q., Leissring, M. A., Tang, W.-J., Charron, M. J., Seeliger, M. A., Saghatelian, A., et al. (2014) · Nature · doi:10.1038/nature13297 · Cited by 254
Insulin Resistance and Alzheimers Disease: Molecular Links & Clinical Implications
Neumann, K., Rojo, L., Navarrete, L., Farias, G., Reyes, P., & Maccioni, R. (2008) · Current Alzheimer Research · doi:10.2174/156720508785908919 · Cited by 236
Brown, B. M., Peiffer, J. J., Taddei, K., Lui, J. K., Laws, S. M., Gupta, V. B., Taddei, T., Ward, V. K., Rodrigues, M. A., Burnham, S., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.107 · Cited by 235
Heart disease as a risk factor for dementia
Hakim, A., Ng, & Turek (2013) · Clinical Epidemiology · doi:10.2147/clep.s30621 · Cited by 229
Is Alzheimer’s disease a systemic disease?
Morris, J. K., Honea, R. A., Vidoni, E. D., Swerdlow, R. H., & Burns, J. M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.04.012 · Cited by 219
Neuropsychological Contributions to the Early Identification of Alzheimer’s Disease
Bondi, M. W., Jak, A. J., Delano-Wood, L., Jacobson, M. W., Delis, D. C., & Salmon, D. P. (2008) · Neuropsychology Review · doi:10.1007/s11065-008-9054-1 · Cited by 216
Mechanisms of Amyloid-β Peptide Clearance: Potential Therapeutic Targets for Alzheimer's Disease
Yoon, S.-S., & AhnJo, S.-M. (2012) · Biomolecules and Therapeutics · doi:10.4062/biomolther.2012.20.3.245 · Cited by 205
Ramanathan, A., Nelson, A. R., Sagare, A. P., & Zlokovic, B. V. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00136 · Cited by 205
A summary risk score for the prediction of Alzheimer disease in elderly persons
Reitz, C., Tang, M.-X., Schupf, N., Manly, J. J., Mayeux, R., & Luchsinger, J. A. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.136 · Cited by 199
Eckman, E. A., Adams, S. K., Troendle, F. J., Stodola, B. A., Kahn, M. A., Fauq, A. H., Xiao, H. D., Bernstein, K. E., & Eckman, C. B. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605827200 · Cited by 196
Self-citationPeroxisomes in brain development and function
Berger, J., Dorninger, F., Forss-Petter, S., & Kunze, M. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.12.005 · Cited by 194
Prospective study of type 2 diabetes and cognitive decline in women aged 70-81 years
Logroscino, G., Kang, J. H., & Grodstein, F. (2004) · BMJ · doi:10.1136/bmj.37977.495729.ee · Cited by 190
Insulin-Degrading Enzyme in the Fight against Alzheimer's Disease
Kurochkin, I. V., Guarnera, E., & Berezovsky, I. N. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.10.008 · Cited by 185
Alzheimer's Disease Puzzle: Delving into Pathogenesis Hypotheses
(2024) · aging and disease · doi:10.14336/ad.2023.0608 · Cited by 183
Antidiabetic agents as a novel treatment for Alzheimer’s and Parkinson’s disease
Nowell, J., Blunt, E., Gupta, D., & Edison, P. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101979 · Cited by 179
“Central insulin resistance may reduce the levels of IDE, which has an important role as a principal regulator of A β levels in neuronal and microglial cells (Farris et al., 2003; Ohyagi et al., 2019).”
BackgroundAmyloid β-degrading cryptidases: insulin degrading enzyme, presequence peptidase, and neprilysin
Malito, E., Hulse, R. E., & Tang, W.-J. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8112-4 · Cited by 176
Sofola, O., Kerr, F., Rogers, I., Killick, R., Augustin, H., Gandy, C., Allen, M. J., Hardy, J., Lovestone, S., & Partridge, L. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1001087 · Cited by 174
Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease
Luchsinger, J. A. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.02.048 · Cited by 171
Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer’s disease?
Nalivaeva, N. N., Beckett, C., Belyaev, N. D., & Turner, A. J. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07510.x · Cited by 169
The physiology of the β‐amyloid precursor protein intracellular domain AICD
Pardossi‐Piquard, R., & Checler, F. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07475.x · Cited by 159
Recent advances in the modeling of Alzheimer’s disease
Sasaguri, H., Hashimoto, S., Watamura, N., Sato, K., Takamura, R., Nagata, K., Tsubuki, S., Ohshima, T., Yoshiki, A., Sato, K., et al. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.807473 · Cited by 157
The involvement of lipid rafts in Alzheimer's disease (Review)
Cordy, J. M., Cordy, J. M., Hooper, N. M., & Turner, A. J. (2006) · Molecular Membrane Biology · doi:10.1080/09687860500496417 · Cited by 157
Exercise programs for people with dementia
Forbes, D., Thiessen, E. J., Blake, C. M., Forbes, S. C., & Forbes, S. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006489.pub3 · Cited by 154
Role of Vascular Risk Factors and Vascular Dysfunction in Alzheimer's Disease
Dickstein, D. L., Walsh, J., Brautigam, H., Stockton, S. D., Gandy, S., & Hof, P. R. (2010) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20155 · Cited by 155
Microglial degeneration in the aging brain - bad news for neurons?
Streit, W. (2008) · Frontiers in Bioscience · doi:10.2741/2937 · Cited by 150
Linking Alzheimer's disease to insulin resistance: the FoxO response to oxidative stress
Manolopoulos, K. N., Klotz, L.-O., Korsten, P., Bornstein, S. R., & Barthel, A. (2010) · Molecular Psychiatry · doi:10.1038/mp.2010.17 · Cited by 150
The Role of Sirtuins in the Control of Metabolic Homeostasis
Yu, J., & Auwerx, J. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04952.x · Cited by 145
IL-4-Induced Selective Clearance of Oligomeric β-Amyloid Peptide1–42 by Rat Primary Type 2 Microglia
Shimizu, E., Kawahara, K., Kajizono, M., Sawada, M., & Nakayama, H. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.9.6503 · Cited by 143
BACE overexpression alters the subcellular processing of APP and inhibits Aβ deposition in vivo
Lee, E. B., Zhang, B., Liu, K., Greenbaum, E. A., Doms, R. W., Trojanowski, J. Q., & Lee, V. M.-Y. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200407070 · Cited by 140
Galectin-3 promotes Aβ oligomerization and Aβ toxicity in a mouse model of Alzheimer’s disease
Tao, C.-C., Cheng, K.-M., Ma, Y.-L., Hsu, W.-L., Chen, Y.-C., Fuh, J.-L., Lee, W.-J., Chao, C.-C., & Lee, E. H. Y. (2020) · Cell Death & Differentiation · doi:10.1038/s41418-019-0348-z · Cited by 138
Wilhelmus, M. M. M., Otte-Höller, I., van Triel, J. J. J., Veerhuis, R., Maat-Schieman, M. L. C., Bu, G., de Waal, R. M. W., & Verbeek, M. M. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070050 · Cited by 138
Yamamoto, M., Horiba, M., Buescher, J. L., Huang, D., Gendelman, H. E., Ransohoff, R. M., & Ikezu, T. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62364-4 · Cited by 137
Carlo, A.-S., Gustafsen, C., Mastrobuoni, G., Nielsen, M. S., Burgert, T., Hartl, D., Rohe, M., Nykjaer, A., Herz, J., Heeren, J., et al. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.2425-12.2013 · Cited by 117
Chyung, J. H., & Selkoe, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304989200 · Cited by 111
Self-citationType 2 diabetes mellitus, dyslipidemia, and Alzheimer’s disease
Carlsson, C. M. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100012 · Cited by 109
Peng, Y., Gao, P., Shi, L., Chen, L., Liu, J., & Long, J. (2020) · Antioxidants & Redox Signaling · doi:10.1089/ars.2019.7763 · Cited by 110
PEDERSEN, W., & FLYNN, E. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.08.003 · Cited by 108
“Indeed, IDE knockout mice were found to have increased production of Ah (Farris et al., 2003; Miller et al., 2003) and features of type 2 diabetes (Farris et al., 2003), including hyperinsulinemia and impaired glucose tolerance.”
BackgroundDolev, I., & Michaelson, D. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404458101 · Cited by 102
Keeney, J. T.-R., Ibrahimi, S., & Zhao, L. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150348 · Cited by 102
Ito, S., Ohtsuki, S., & Terasaki, T. (2006) · Neuroscience Research · doi:10.1016/j.neures.2006.07.006 · Cited by 99
Alzheimer’s Disease and Inflammaging
Kosyreva, A., Sentyabreva, A., Tsvetkov, I., & Makarova, O. (2022) · Brain Sciences · doi:10.3390/brainsci12091237 · Cited by 98
Abbatecola, A. M., Lattanzio, F., Molinari, A. M., Cioffi, M., Mansi, L., Rambaldi, P., DiCioccio, L., Cacciapuoti, F., Canonico, R., & Paolisso, G. (2010) · Diabetes Care · doi:10.2337/dc09-2030 · Cited by 93
ERK1/2 is an endogenous negative regulator of the γsecretase activity
Kim, S., Park, H., Hong, H. S., Baik, E. J., Jung, M. W., & Mook‐Jung, I. (2006) · The FASEB Journal · doi:10.1096/fj.05-4055fje · Cited by 92
Bukhari, H., Glotzbach, A., Kolbe, K., Leonhardt, G., Loosse, C., & Müller, T. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.05.005 · Cited by 88
Simon, E., Obst, J., & Gomez-Nicola, D. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2018.01.059 · Cited by 83
Remembering your A, B, C's: Alzheimer's disease and ABCA1
Lewandowski, C. T., Laham, M. S., & Thatcher, G. R. J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.01.011 · Cited by 76
Bouter, Y., Kacprowski, T., Weissmann, R., Dietrich, K., Borgers, H., Brauß, A., Sperling, C., Wirths, O., Albrecht, M., Jensen, L. R., et al. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00075 · Cited by 76
Ponce-Lopez, T. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094209 · Cited by 75
Neuroimmune contributions to Alzheimer’s disease: a focus on human data
Haage, V., & De Jager, P. L. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01637-0 · Cited by 74
Cathepsin D regulates cerebral Aβ42/40 ratios via differential degradation of Aβ42 and Aβ40
Suire, C. N., Abdul-Hay, S. O., Sahara, T., Kang, D., Brizuela, M. K., Saftig, P., Dickson, D. W., Rosenberry, T. L., & Leissring, M. A. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00649-8 · Cited by 73
State of the science on brain insulin resistance and cognitive decline due to Alzheimer's disease
Rhea, E. M., Leclerc, M., Yassine, H. N., Capuano, A. W., Tong, H., Petyuk, V. A., Macauley, S. L., Fioramonti, X., Carmichael, O., Calon, F., et al. (2023) · Aging and disease · doi:10.14336/ad.2023.0814 · Cited by 70
Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus
Sim, A. Y., Barua, S., Kim, J. Y., Lee, Y.-H., & Lee, J. E. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.708547 · Cited by 62
Modulation of β-Amyloid Fibril Formation in Alzheimer’s Disease by Microglia and Infection
Brown, M. R., Radford, S. E., & Hewitt, E. W. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.609073 · Cited by 67
Campos-Peña, V., Toral-Rios, D., Becerril-Pérez, F., Sánchez-Torres, C., Delgado-Namorado, Y., Torres-Ossorio, E., Franco-Bocanegra, D., & Carvajal, K. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6768 · Cited by 58
Zhao, Y., Zhang, Y., Zhou, M., Wang, S., Hua, Z., & Zhang, J. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.03.034 · Cited by 57
Endosomal trafficking in metabolic homeostasis and diseases
Gilleron, J., & Zeigerer, A. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00737-9 · Cited by 57
Song, J., & Kim, O. Y. (2018) · Clinical Nutrition Research · doi:10.7762/cnr.2018.7.1.1 · Cited by 53
Nutritional interventions for Alzheimer's prevention: a clinical precision medicine approach
Schelke, M. W., Hackett, K., Chen, J. L., Shih, C., Shum, J., Montgomery, M. E., Chiang, G. C., Berkowitz, C., Seifan, A., Krikorian, R., et al. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13070 · Cited by 51
Ito, S., Ueno, T., Ohtsuki, S., & Terasaki, T. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06708.x · Cited by 48
Fasting Insulin Levels and Cognitive Decline in Older Women without Diabetes
van Oijen, M., Okereke, O. I., Kang, J. H., Pollak, M. N., Hu, F. B., Hankinson, S. E., & Grodstein, F. (2008) · Neuroepidemiology · doi:10.1159/000126909 · Cited by 44
Li, G., Kim, C., Kim, J., Yoon, H., Zhou, H., & Kim, J. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150024 · Cited by 42
Hernández‐Guillamon, M., Delgado, P., Ortega, L., Pares, M., Rosell, A., García‐Bonilla, L., Fernández‐Cadenas, I., Borrell‐Pagès, M., Boada, M., & Montaner, J. (2009) · Journal of Neuroscience Research · doi:10.1002/jnr.22034 · Cited by 39
Zheng, B., Su, B., Ahmadi‐Abhari, S., Kapogiannis, D., Tzoulaki, I., Riboli, E., & Middleton, L. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13349 · Cited by 34
Morrone, C. D., Liu, M., Black, S. E., & McLaurin, J. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00064 · Cited by 26
Impact of Genetic Risk Factors for Alzheimer’s Disease on Brain Glucose Metabolism
Cho, S., Lee, H., & Seo, J. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02297-x · Cited by 25
Loss of renal SNX5 results in impaired IDE activity and insulin resistance in mice
Li, F., Yang, J., Villar, V. A. M., Asico, L. D., Ma, X., Armando, I., Sanada, H., Yoneda, M., Felder, R. A., Jose, P. A., et al. (2018) · Diabetologia · doi:10.1007/s00125-017-4482-1 · Cited by 22
Du, J., Sun, B., Chen, K., Fan, L., & Wang, Z. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.04.148 · Cited by 19
Lauer, A. A., Mett, J., Janitschke, D., Thiel, A., Stahlmann, C. P., Bachmann, C. M., Ritzmann, F., Schrul, B., Müller, U. C., Stein, R., et al. (2020) · Aging Cell · doi:10.1111/acel.13264 · Cited by 15
Querfurth, H., Marshall, J., Parang, K., Rioult-Pedotti, M. S., Tiwari, R., Kwon, B., Reisinger, S., & Lee, H.-K. (2022) · PLOS ONE · doi:10.1371/journal.pone.0261696 · Cited by 9
Iwasaki, K., Carapeto, P., Abarca, C., Hela, F., Sanjines, S., Pena, S., Le, S., Pan, H., Jackson, M., Cahill, C., et al. (2026) · JCI Insight · doi:10.1172/jci.insight.197310 · Cited by 4
Luchsinger, J. A. (2010) · Research and Perspectives in Alzheimer's Disease · doi:10.1007/978-3-642-04300-0_7 · Cited by 3
Metadata
- Authors
- Farris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E. A., Frosch, M. P., Eckman, C. B., Tanzi, R. E., Selkoe, D. J., & Guénette, S.
- Affiliations
- Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Boston, MA 02115; Harvard Medical School, Boston, MA 02115; Center for Aging, Genetics, and Neurodegeneration, Department of Neurology, Massachusetts General Hospital, Boston, MA 02129; and Mayo Clinic, Jacksonville, FL 32224
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2003-03-12
- Volume
- 100
- Issue
- 7
- Pages
- 4162-4167
- ISSN
- 0027-8424
- 1091-6490
- Cited by
- 1,286
- References
- 11
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.